New nomenclature codes for stereotactic radiotherapy introduced in Belgium

27

May 2020

In April 2020, the Belgian National Institute for Health and Disability Insurance (INAMI-RIZIV) introduced four new nomenclature codes for stereotactic radiotherapy (Belgian Monitor of April 27, 2020). Physicians also must register data on provided stereotactic radiotherapy series in the specific module of Cancer Registry Foundation.

New services belong to a category 4-bis of the INAMI nomenclature of health services for radiotherapy (article 18 §1 and article 19).

  • 444636-444640 Fixed fees for a series of stereotactic radiotherapy in a patient who meets the criteria in category 4bis, with primary tumors (except brain tumors)
  • 444651-444662 Fixed fees for a series of stereotactic radiotherapy in a patient who meets the criteria in category 4bis, with oligometastases (except brain metastases)
  • 444673-444684 Fixed fees for a series of stereotactic radiotherapy in a patient who meets the criteria in category 4bis, with malignant brain tumors and brain metastases
  • 444695-444706 Fixed fees for a series of stereotactic radiotherapy in a patient who meets the criteria in category 4bis, with non-malignant brain tumors and arteriovenous malformations (AVM)

Each of these services is remunerated at K 2000 (actual tariff is € 2,581.73)

The reimbursement conditions include registration data in the Cancer Registry Foundation. Personal data will be kept for 30 years after the patients' death. The purposes of this register are:

  • Quality control and monitoring of the costs of the care provided
  • Long-term prospective monitoring of mortality, recurrences and secondary cancers in order to assess and adapt the national policies

A multidisciplinary recommendation for this radiotherapy technique is required prior to each treatment series. It is a complex external irradiation with at least 6 Gy per fraction, which allows affecting the lesion with high precision.

The location of the irradiated lesion can be intracerebral or extracerebral. Stereotaxic radiotherapy to treat extracerebral lesions - primary tumors and - oligometastatic lesions (maximum of five lesions)

A maximum number of services that can be applied to one patient:

  • Three series of stereotactic radiotherapy for a patient, per 12 months and per organ
  • In total six times per 12 months for the whole body (including the brain)

Only one series of treatments can be invoiced per brain treatment procedure regardless of the number of lesions.

See the full details here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

11

May 2021

In late April and early May 2021, three more health apps were introduced in the Directory of digital health applications (DiGAs) at the Federal Office for Drugs and Medical Devices (BfArM) and thus became reimbursable. These apps can be prescribed by physicians and psychotherapists and will be reimbursed by health insurers. In total, fifteen health apps are now available at the DiGA Directory.

Read more

05

May 2021

Transcatheter aortic valve implantation (TAVI/TAVR) in severe aortic stenosis treatment across all surgical risk groups was being evaluated within the "New Methods" framework since 2019. On April 26, 2021, the Decision Forum for "New Methods" made a positive coverage decision for TAVI/TAVR to treat patients with severe aortic stenosis across all surgical risk groups.

Read more

04

May 2021

In April 2021, the Clinical Coding and Schedule Development (CCSD) working group, which develops and maintains procedural and diagnostics nomenclature for private payers in England, has published Bulletins 0176 and 0073 with changes to be implemented not later than August 01, 2021. Four new procedure codes related to men's health and breast surgery and one new companion diagnostic code were introduced.

Read more

03

May 2021

On April 22, 2021, the List of reimbursable implants and invasive medical devices, maintained by the National Institute for Health and Disability Insurance (INAMI), was updated with the corresponding Nominative lists of brand-specific devices. Two new Nominative lists with reimbursable devices used for peripheral vascular interventions were introduced.

Read more

22

Apr 2021

The revised EBM (German Uniform Evaluation Standard) catalog came into force on April 1, 2021. Two new EBM codes for IVD tests were introduced, and reimbursement conditions for two IVD tests were amended.

Read more